Abbott announces CE Mark for world’s longest coronary drug eluting stent
21 May 2013 | By Abbott
Abbott announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System...
List view / Grid view
Abbott Laboratories is an American worldwide healthcare company. With headquarters in Lake Bluff, Illinois, it has 94,000 employees and operates in more than 150 countries.
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
21 May 2013 | By Abbott
Abbott announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System...
Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.
18 April 2013 | By Abbott
TECNIS® Toric 1-Piece intraocular lens has received U.S. FDA approval...
Abbott today announced the global launch of the ACCELERATOR® a3600, a next generation automation solution, to help laboratories address the need to process tests faster while handling increased volume. Advances in technology and automation within the lab have led to more timely results leading to improved patient care. Automation systems…
Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in partnership with BG Medicine, Inc., (NASDAQ: BGMD) to run on Abbott’s ARCHITECT immunochemistry platform.
20 March 2013 | By Abbott
"We appreciate the FDA's dedication of time and resources..."
11 March 2013 | By Abbott
Abbott announced positive long-term results...
10 March 2013 | By Abbott
Data from the EVEREST II study...
21 February 2013 | By Abbott
Abbott will collaborate with Janssen Biotech and Pharmacyclics to explore the benefits of Abbott's proprietary FISH technology...
An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.1 Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced today CE Marking (Conformité…
8 January 2013 | By Abbott
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States...
3 January 2013 | By Abbott
FDA approval - XIENCE Xpedition™ Everolimus Eluting Coronary Stent System...
2 January 2013 | By Abbott
Abbott has completed the separation of its research-based pharmaceuticals business...
17 December 2012 | By Abbott
New assay measures testosterone levels to help diagnose related conditions...
13 December 2012 | By Abbott
Acute chest pain is one of the most common reasons people seek emergency care...